Previously, Bagnall was employed as the executive vice president and member of the board of directors of
ADVENTRX Pharmaceuticals.
11 November 2011 - Rodman & Renshaw LLC will act as sole book-runner in a planned offering of common stock and warrants by
Adventrx Pharmaceuticals Inc (AMEX:ANX), the US speciality pharmaceuticals firm said on Thursday.
US speciality pharmaceutical firm
Adventrx Pharmaceuticals (AMEX:ANX) has closed its previously announced takeover of biotechnology firm SynthRx in exchange for 2.8m common shares.
Currently, Dr Goldberg is a member of the board of Navidea Biopharmaceuticals as well as a director of Alliqua, Urigen Pharmaceuticals and
Adventrx Pharmaceuticals.
Biopharmaceutical company
ADVENTRX Pharmaceuticals Inc (NYSE MKT:ANX) said on Thursday that it intends to develop ANX-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease, which affects an estimated 8m to 12m people in the US.
SynthRx develops a purified form of a rheologic and antithrombotic agent, poloxamer 188.Country: , USASector: PharmaceuticalsTarget: SynthRx IncBuyer:
ADVENTRX Pharmaceuticals IncType: Corporate acquisitionFinancing: All-stockStatus: Closed
(YAX603) NICHOLAS JON VIRCA -
ADVENTRX PHARMACEUTICALS INC (ANX).
Biopharmaceutical company
ADVENTRX Pharmaceuticals Inc (NYSE MKT:ANX) said on Thursday that this quarter it plans to initiate the phase 3 clinical study of ANX-188 in sickle cell disease.
US speciality pharmaceutical firm
Adventrx Pharmaceuticals (AMEX:ANX) said it has agreed to buy biotechnology firm SynthRx in exchange for 4% of its shares.
(RAX262) NICHOLAS VIRCA -
ADVENTRX PHARMACEUTICALS INC (AVRX).
Biopharmaceutical company
ADVENTRX Pharmaceuticals Inc (NYSE MKT:ANX) revealed on Thursday a change in its corporate name to Mast Therapeutics Inc with effect from 11 March 2013.
ADVENTRX Pharmaceuticals Inc (NYSE MKT: ANX), a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions, announced on September 7, 2012, that it has named Ted W Love, MD as its director.